EDITORIAL GOVERNANCE & MEDICAL REVIEW
-
✓
Content Author: Ms. Hannah Matthews (B.Sc. - Biochemistry)
-
✓
Medically Reviewed By: Dr. N Kumar, MD, DM (Neurology), Member of the International Society for Stem Cell Research (ISSCR).
-
✓
State Medical Council Registration No.: Medical Registration Verified | Member, Indian Academy of Neurology
-
✓
Expert Scientific Reviewer: Dr. Harinath P, PhD (Stem Cell Biology & Regenerative Immunology)
-
✓
Clinical Governance Protocol:
SOP-IBM-09(Investigational Cellular Protocol)
Clinical Overview & Biological Mechanism
Pathology, cellular action of Mesenchymal Stem Cells (MSCs), and investigational intent
The Pathology:
Inclusion Body Myositis (IBM) is an acquired, age-related inflammatory myopathy marked by progressive muscle wasting, rimmed vacuoles, and cytotoxic T-cell infiltration, predominantly targeting deep finger flexors and quadriceps.
The Cellular Mechanism:
Umbilical cord-derived Mesenchymal Stem Cells (UC-MSCs) exert dual immunomodulatory and trophic effects:
- Downregulate cytotoxic CD8+ T-cell infiltration and suppress pro-inflammatory cytokines (IFN-γ, TNF-α).
- Secrete paracrine trophic factors (IGF-1, VEGF, HGF) to counter muscle atrophy and promote microvascular tissue support.
- Modulate macrophage activity to reduce muscle fiber degradation and interstitial fibrosis.
Candidate Screening & Safety Triage
Inclusion criteria, absolute safety exclusions, and pre-arrival diagnostic clearance
Eligible Profiles:
- Confirmed IBM diagnosis via muscle biopsy (rimmed vacuoles, amyloid/protein inclusions), positive anti-cN1A (cytosolic 5'-nucleotidase 1A) serology, or characteristic clinical MRI patterns.
- Progressive weakness in knee extension (quadriceps) or finger flexors that is refractory to conventional corticosteroids and immunosuppressants.
- Baseline forced vital capacity (FVC) > 60% of predicted value, clinically cleared for commercial air travel.
- Severe advanced dysphagia with imminent aspiration pneumonia risks (requires acute ENT/gastroenterology management).
- Active malignancy, severe untreated cardiac failure, or active systemic infections.
Potential Improvements & Realistic Clinical Boundaries
Reported functional goals alongside documented non-responder rates and realistic limits
- Outcomes vary depending on the extent of existing muscle fibro-fatty replacement. Stem cell therapy is an adjunctive intervention and does not restore vanished muscle tissue.
Clinical Safety Profile & Anticipated Adverse Reactions
Anticipated transient reactions, procedural safeguards, and long-term surveillance
- Clinical-grade, unmanipulated allogeneic MSCs maintain a documented safety profile, but patients may experience transient, self-limiting reactions:
Common & Transient (Day 1–3):
Low-grade post-infusion fever (< 38°C / 100.4°F), temporary muscle fatigue, mild headache, or minor cannula site tenderness.
Rare Risks:
Allergic hypersensitivity reactions (infusions occur under continuous vital sign tracking and bedside emergency management).
Step-by-Step Treatment Schedule & In-Hospital Workflow
Structured clinical itinerary during your stay in India (4 to 6 Days)
Day 1 (Comprehensive Baseline Workup):
- In-person neurological exam, grip strength dynamometry, and IBM Functional Rating Scale (IBM-FRS) baseline scoring.
None:
Days 2–3 (Cell Delivery & Supervised Rehabilitation):
- Administered intravenous (IV) infusion and/or targeted local intramuscular delivery of certified viable UC-MSCs.
- Supervised physical therapy focusing on eccentric muscle protection, transfer coaching, and breathing exercises.
Days 4–5 (Post-Infusion Assessment & Rest):
- Clinical review of vital stability, post-procedure check, and issuance of a personalized home rehabilitation protocol.
Day 6 (Discharge & Travel Clearance):
- Final neurological review and issuance of fit-to-fly documentation.
Why Receive Care at Our Specialized Center in India?
Super-specialist clinical oversight, cGMP cleanroom facilities, and high cell viability
Treatment Costs & Comparative Package Inclusions
Transparent international pricing with comprehensive hospital, cellular, and logistical inclusions
(Comprehensive package covering targeted UC-MSCs, procedural suites, specialist fees, and 12-month monitoring).
(Administered under strict ISO Class 5 cleanroom standards and institutional ethics oversight).
| Country / Region | Typical Package Range | Waiting Period | Clinical Accreditation |
|---|---|---|---|
| India (Our Specialized Centers) | $5,200 – $7,800 USD | 1 – 2 Weeks | NABH / JCI Accredited |
| United States | $35,000 – $65,000 USD | 3 – 6 Months | Clinical Trial Gated |
| Germany & Switzerland | $28,000 – $55,000 USD | 2 – 4 Months | Private Specialty Only |
| Panama / Mexico | $18,000 – $32,000 USD | 2 – 4 Weeks | Variable Regional |
Dedicated Support for International Patients & Families
Full medical concierge care, government visa assistance, and airport transit
Medical Visa (MED) Processing:
Official visa invitation letters issued within 24–48 hours for the patient and accompanying caregiver (with FRRO assistance).
Dedicated Case Coordinator:
Single bilingual coordinator assisting with documentation, scheduling, and hospital logistics.
Airport & Ground Transit:
Complimentary private airport pick-up/drop-off with wheelchair-accessible transport.
Language & Dietary Care:
Multi-language translators (Arabic, Russian, French) and custom international meal arrangements (Halal, Vegetarian, Continental).
Logistics & Accessible Accommodation
Daycare outpatient protocol, nearby wheelchair-accessible partner lodging, and daily transfers
Daycare Model:
Patients undergo treatment and rehabilitation in morning sessions and return to private lodging each afternoon.
Direct Daily Commute:
Arranged transfers between local lodging and the medical center to prevent travel fatigue.
Regulatory Disclosures & Ethical Declarations
Statutory compliance under ICMR-DBT National Guidelines and vital medication advisories
Peer-Reviewed Clinical Literature & Scientific Context
Published scientific trials, systematic reviews, and official registry citations validating cellular safety and therapeutic mechanisms
Scientific Notice on Study Types:
Scientific Scope & Trial Note: Inclusion Body Myositis exhibits both autoimmune and myodegenerative features. References 1 and 3 detail the paracrine immunomodulatory mechanisms of Mesenchymal Stem Cells in myositis disease models and broad neuromuscular cohorts. References 2 and 4 describe the clinical complexities, diagnostic biomarkers, and therapeutic boundaries in refractory IBM.
Preclinical Efficacy of Adipose-Derived Cell Therapies for Myositis (PMC / NIH, 2025)
Preclinical efficacy of adipose-derived cell therapies for inflammatory myopathies. Stem Cell Res Ther / PMC, 2025; PMCID: PMC12445652.
Naddaf et al. (Continuum: Lifelong Learning in Neurology, 2025)
Naddaf E. Inclusion Body Myositis. Continuum (Minneap Minn), 2025; 31(5): 1372–1384. PMID: 41037166.
Klimczak et al. (Stem Cells International, 2018)
Klimczak Z, et al. Mesenchymal Stem/Stromal Cells for Skeletal Muscle Regeneration in Neuromuscular Disorders. Stem Cells Int, 2018; PMID: 29854005.
Al-Lozi et al. / Muscle & Nerve Translational Insights
Current paradigms in refractory Inclusion Body Myositis and emerging cellular avenues. Muscle Nerve, 2022; PMID: 36537974.
Frequently Asked Questions
Evidence-based answers to key clinical, safety, cost, and travel inquiries regarding Inclusion Body Myositis (IBM)